Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: A preliminary open label study

Neuropsychiatric Disease and Treatment

Volumn 9, Issue , 2013, Pages 243-251

  Fornaro, Michele ^a   McCarthy, Michael J ^b,c   De Berardis, Domenico ^d   De Pasquale, Concetta ^a   Tabaton, Massimo ^e   Martino, Matteo ^e   Colicchio, Salvatore ^f   Cattaneo, Carlo Ignazio ^g   D'Angelo, Emanuela ^h   Fornaro, Pantaleo ^e  

^a UNIVERSITY OF CATANIA   (Italy)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ASL 4   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

^f CATHOLIC UNIVERSITY   (Italy)

^g ASL 13   (Italy)

^h ASL 3   (Italy)

Author keywords

Acute bipolar depression; Adjunctive treatment; Agomelatine; Bipolar disorder type II

Indexed keywords

AGOMELATINE; LITHIUM SALT; VALPROIC ACID;

ADJUVANT THERAPY; ADOLESCENT; ADULT; ARTICLE; BEDTIME DOSAGE; BIPOLAR DEPRESSION; BIPOLAR II DISORDER; BODY MASS; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HAMILTON SCALE; HUMAN; HYPOMANIA; INSOMNIA; MAJOR DEPRESSION; MALE; MANIA; MULTICENTER STUDY; OPEN STUDY; PILOT STUDY; PITTSBURGH SLEEP QUALITY INDEX; TREATMENT OUTCOME; VERTIGO; YOUNG MANIA RATING SCALE;

EID: 84874348277     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S41557     Document Type: Article

References (80)

1. APA. Diagnostic and Statistical Manual for Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.
2. Ketter TA, Calabrese JR. Stabilization of mood from below versus above baseline in bipolar disorder: a new nomenclature. J Clin Psychiatry. 2002; 63(2):146-151.
3. Swartz HA, Thase ME. Pharmacotherapy for the treatment of acute bipolar II depression: current evidence. The Journal of Clinical Psychiatry. 2011;72(3):356-366.
4. Rybakowski JK. Bipolarity and inadequate response to antidepressant drugs: clinical and psychopharmacological perspective. Journal of Affective Disorders. 2012;136(1-2):e13-e19.
5. Fornaro M, Martino M, De Pasquale C, Moussaoui D. The argument of antidepressant drugs in the treatment of bipolar depression: mixed evidence or mixed states? Expert Opinion on Pharmacotherapy. 2012;13(14):2037-2051.
6. den Boer JA, Bosker FJ, Meesters Y. Clinical effcacy of agomelatine in depression: the evidence. International Clinical Psychopharmacology. 2006;21(Suppl 1):S21-S24.
7. Montgomery SA, Kasper S. Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. International Clinical Psychopharmacolog y. 2007;22(5):283-291.
8. Kennedy SH, Young AH, Blier P. Strategies to achieve clinical effectiveness: refning existing therapies and pursuing emerging targets. Journal of Affective Disorders. 2011;132(Suppl 1):S21-S28.
9. Fornaro M, Prestia D, Colicchio S, Perugi G. A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation. Current Neuropharmacology. 2010;8(3):287-304.
10. Calabrese JR, Guelf JD, Perdrizet-Chevallier C. Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. Bipolar Disorders. 2007;9(6):628-635.
11. Eppel AB. Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. Bipolar Disorders. 2008;10(6):749-750.
12. Angst J, Marneros A. Bipolarity from ancient to modern times: conception, birth and rebirth. Journal of Affective Disorders. 2001;67(1-3): 3-19.
13. Lopez-Munoz F, Alamo C. Cartesian theories on the passions, the pineal gland and the pathogenesis of affective disorders: an early forerunner. Psychological Medicine. 2011;41(3):449-451.
14. Wehr TA, Goodwin FK. Rapid cycling in manic-depressives induced by tricyclic antidepressants. Archives of General Psychiatry. 1979;36(5): 555-559.
15. McCarthy MJ, Welsh DK. Cellular circadian clocks in mood disorders. Journal of Biological Rhythms. 2012;27(5):339-352.
16. Jackson A, Cavanagh J, Scott J. A systematic review of manic and depressive prodromes. Journal of Affective Disorders. 2003;74(3): 209-217.
17. Monteleone P, Martiadis V, Maj M. Circadian rhythms and treatment implications in depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2011;35(7):1569-1574.
18. Racagni G, Riva MA, Molteni R, et al. Mode of action of agomelatine: synergy between melatonergic and 5-HT2C receptors. The world journal of biological psychiatry. The Offcial Journal of the World Federation of Societies of Biological Psychiatry. 2011;12(8):574-587.
19. Murray G, Harvey A. Circadian rhythms and sleep in bipolar disorder. Bipolar Disorders. 2010;12(5):459-472.
20. Mazza M, Mandelli L, Martinotti G, et al. Further evidence supporting the association between 5HTR2C gene and bipolar disorder. Psychiatry Research. 2010;180(2-3):151-152.
21. Fornaro M, Aguglia E, Dell'Osso L, Perugi G. Could the underestimation of bipolarity obstruct the search for novel antidepressant drugs? Expert Opinion on Pharmacotherapy. 2011;12(18):2817-2831.
22. First MB, Spitzer RI, Gibbon M, Williams BJW. Structured Clinical Interview for DSM-IV Axis I Disorders. Washington, DC: American Psychiatric Press; 1997.
23. Hamilton M. Development of a rating scale for primary depressive illness. The British Journal of Social and Clinical Psychology. 1967;6(4):278-296.
24. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modifcation of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Research. 1997;73(3): 159-171.
25. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. The British Journal of Psychiatry: The Journal of Mental Science. 1978;133:429-435.
26. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Research. 1989;28(2):193-213.
27. Julious SA. Sample size of 12 per group rule of thumb for a pilot study. Pharmaceutical Statistics. 2005;4(4):287-291.
28. Muller MJ, Himmerich H, Kienzle B, Szegedi A. Differentiating moderate and severe depression using the Montgomery-Asberg Depression Rating Scale (MADRS). Journal of Affective Disorders. 2003;77(3): 255-260.
29. Howland RH. Publication bias and outcome reporting bias: agomelatine as a case example. Journal of Psychosocial Nursing and Mental Health Services. 2011;49(9):11-14.
30. Millan MJ, Gobert A, Lejeune F, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. The Journal of Pharmacology and Experimental Therapeutics. 2003;306(3):954-964.
31. Duxon MS, Kennett GA, Lightowler S, Blackburn T P, Fone KC. Activation of 5-HT2B receptors in the medial amygdala causes anxiolysis in the social interaction test in the rat. Neuropharmacology. 1997;36(4-5):601-608.
32. Malhi GS, Adams D, Berk M. Medicating mood with maintenance in mind: bipolar depression pharmacotherapy. Bipolar Disorders. 2009;11(Suppl 2):55-76.
33. Montgomery SA, Kennedy SH, Burrows GD, Lejoyeux M, Hindmarch I. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, doubleblind, placebo-controlled discontinuation study. International Clinical Psychopharmacology. 2004;19(5):271-280.
34. Montejo A, Majadas S, Rizvi SJ, Kennedy SH. The effects of agomelatine on sexual function in depressed patients and healthy volunteers. Human Psychopharmacology. 2011;26(8):537-542.
35. Niles L P, Sathiyapalan A, Bahna S, Kang NH, Pan Y. Valproic acid upregulates melatonin MT1 and MT2 receptors and neurotrophic factors CDNF and MANF in the rat brain. The International Journal of Neuropsychopharmacology/Offcial Scientifc Journal of the Collegium Internationale Neuropsychopharmacologicum. 2012;15(9):1343-1350.
36. Hallam KT, Olver JS, Horgan JE, McGrath C, Norman TR. Low doses of lithium carbonate reduce melatonin light sensitivity in healthy volunteers. The International Journal of Neuropsychopharmacology/ Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum. 2005;8(2):255-259.
37. Levitan MN, Papelbaum M, Nardi AE. A review of preliminary observations on agomelatine in the treatment of anxiety disorders. Experimental and Clinical Psychopharmacology. 2012;20(6):504-509.
38. Fornaro M. Switching from serotonin reuptake inhibitors to agomelatine in patients with refractory obsessive-compulsive disorder: a 3 month follow-up case series. Annals of General Psychiatry. 2011;10(1):5.
39. Fornaro M. Agomelatine in the treatment of panic disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2011;35(1): 286-287.
40. De Berardis D, Serroni N, Marini S, et al. Agomelatine augmentation of escitalopram therapy in treatment-resistant obsessive-compulsive disorder: a case report. Case Reports in Psychiatry. 2012;2012:642-752.
41. De Berardis D, Serroni N, Campanella D, et al. A case of obsessive-compulsive disorder successfully treated with agomelatine monotherapy. Journal of Clinical Psychopharmacology. 2012;32(2):289-290.
42. De Berardis D, Serroni N, Marini S, Moschetta FS, Martinotti G, Di Giannantonio M. Agomelatine for the treatment of posttraumatic stress disorder: a case report. Annals of Clinical Psychiatry: Offcial Journal of the American Academy of Clinical Psychiatrists. 2012;24(3):241-242.
43. Crippa JA, Hallak JE, Zuardi AW, Chagas MH, Quevedo J, Nardi AE. Agomelatine in the treatment of social anxiety disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2010;34(7): 1357-1358.
44. Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. The Journal of Clinical Psychiatry. 2007;68(11):1723-1732.
45. Kasper S, Hajak G, Wulff K, et al. Effcacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. The Journal of Clinical Psychiatry. 2010;71(2):109-120.
46. Quera-Salva MA, Hajak G, Philip P, et al. Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and effcacy in major depressive disorder patients. International Clinical Psychopharmacology. 2011;26(5):252-262.
47. Sharpley AL, Rawlings NB, Brain S, McTavish SF, Cowen PJ. Does agomelatine block 5-HT2C receptors in humans? Psychopharmacology. 2011;213(2-3):653-655.
48. Colombo C, Benedetti F, Barbini B, Campori E, Smeraldi E. Rate of switch from depression into mania after therapeutic sleep deprivation in bipolar depression. Psychiatry Research. 1999;86(3):267-270.
49. Rojo JE, Gibert K, Cobo J, Rodriguez-Cano E, Vallejo J. Onset of antidepressant action: a pharmacological question? Human Psychopharmacology. 2005;20(6):425-433.
50. Baglioni C, Battagliese G, Feige B, et al. Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies. Journal of Affective Disorders. 2011;135(1-3):10-19.
51. Matthews PR. Effcacy of antidepressants: similar but different. The International Journal of Neuropsychopharmacology/Offcial Scientifc Journal of the Collegium Internationale Neuropsychopharmacologicum. 2011;14(10):1433-1437.
52. Wichniak A, Wierzbicka A, Jernajczyk W. Sleep and antidepressant treatment. Current Pharmaceutical Design. 2012;18(36):5802-5817.
53. Lewy AJ, Lefer BJ, Emens JS, Bauer VK. The circadian basis of winter depression. Proceedings of the National Academy of Sciences of the United States of America. 2006;103(19):7414-7419.
54. Leverich GS, Altshuler LL, Frye MA, et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. The American Journal of Psychiatry. 2006;163(2):232-239.
55. Ghaemi SN, Ostacher MM, El-Mallakh RS, et al. Antidepressant discontinuation in bipolar depression: a Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety. The Journal of Clinical Psychiatry. 2010;71(4):372-380.
56. Kripke DF, Judd LL, Hubbard B, Janowsky DS, Huey LY. The effect of lithium carbonate on the circadian rhythm of sleep in normal human subjects. Biological Psychiatry. 1979;14(3):545-548.
57. Li J, Lu WQ, Beesley S, Loudon AS, Meng QJ. Lithium impacts on the amplitude and period of the molecular circadian clockwork. PloS One. 2012;7(3):e33292.
58. Johansson AS, Brask J, Owe-Larsson B, Hetta J, Lundkvist GB. Valproic acid phase shifts the rhythmic expression of Period2::Luciferase. Journal of Biological Rhythms. 2011;26(6):541-551.
59. McCarthy MJ, Nievergelt CM, Shekhtman T, Kripke D F, Welsh DK, Kelsoe JR. Functional genetic variation in the Rev-Erbalpha pathway and lithium response in the treatment of bipolar disorder. Genes, Brain, and Behavior. 2011;10(8):852-861.
60. Gruber J, Miklowitz DJ, Harvey AG, et al. Sleep matters: sleep functioning and course of illness in bipolar disorder. Journal of Affective Disorders. 2011;134(1-3):416-420.
61. Scott J. Clinical parameters of circadian rhythms in affective disorders. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology. 2011;21(Suppl 4):S671-S675.
62. Murray G, Allen NB, Trinder J, Burgess H. Is weakened circadian rhythmicity a characteristic of neuroticism? Journal of Affective Disorders. 2002;72(3):281-289.
63. Bullock B, Judd F, Murray G. Social rhythms and vulnerability to bipolar disorder. Journal of Affective Disorders. 2011;135(1-3):384-388.
64. Ehlers CL, Frank E, Kupfer DJ. Social zeitgebers and biological rhythms. A unified approach to understanding the etiology of depression. Archives of General Psychiatry. 1988;45(10):948-952.
65. Fornaro M, Bandini F, Ogliastro C, et al. Electroretinographic assessment in major depressed patients receiving duloxetine: might differences between responders and non-responders indicate a differential biological background? Journal of Affective Disorders. 2011;135(1-3): 154-159.
66. Konturek PC, Brzozowski T, Konturek SJ. Gut clock: implication of circadian rhythms in the gastrointestinal tract. Journal of Physiology and Pharmacology: An Offcial Journal of the Polish Physiological Society. 2011;62(2):139-150.
67. Nisembaum LG, Velarde E, Tinoco AB, et al. Light-dark cycle and feeding time differentially entrains the gut molecular clock of the goldfsh (Carassius auratus). Chronobiology International. 2012;29(6):665-673.
68. Huang W, Ramsey KM, Marcheva B, Bass J. Circadian rhythms, sleep, and metabolism. The Journal of Clinical Investigation. 2011;121(6): 2133-2141.
69. Reiter RJ, Rosales-Corral S, Coto-Montes A, et al. The photoperiod, circadian regulation and chronodisruption: the requisite interplay between the suprachiasmatic nuclei and the pineal and gut melatonin. Journal of Physiology and Pharmacology: An Offcial Journal of the Polish Physiological Society. 2011;62(3):269-274.
70. Albrecht U. Circadian rhythms and sleep - the metabolic connection. Pflugers Archiv: European Journal Of Physiology. 2012;463(1): 23-30.
71. Fountoulakis KN. Disruption of biological rhythms as a core problem and therapeutic target in mood disorders: the emerging concept of 'rhythm regulators'. Annals of General Psychiatry. 2010;9:3.
72. Fornaro M, Perugi G, Gabrielli F, et al. Lifetime co-morbidity with different subtypes of eating disorders in 148 females with bipolar disorders. Journal of Affective Disorders. 2010;121(1-2):147-151.
73. Muhlhans B, Olbrich K, de Zwaan M. Night eating syndrome and nocturnal eating - what is it all about? Psychotherapie, Psychosomatik, Medizinische Psychologie. 2009;59(2):50-56.
74. Goel N, Stunkard AJ, Rogers NL, et al. Circadian rhythm profles in women with night eating syndrome. Journal of Biological Rhythms. 2009;24(1):85-94.
75. McElroy SL, Frye MA, Hellemann G, et al. Prevalence and correlates of eating disorders in 875 patients with bipolar disorder. Journal of Affective Disorders. 2011;128(3):191-198.
76. Montgomery SA. Why do we need new and better antidepressants? International Clinical Psychopharmacology. 2006;21(Suppl 1): S1-S10.
77. Kasper S, Corruble E, Hale A, Lemoine P, Montgomery SA, QueraSalva MA. Antidepressant effcacy of agomelatine versus SSRI/SNRI: results from a pooled analysis of head-to-head studies without a placebo control. International Clinical Psychopharmacology. 2012;28(1): 12-9.
78. Kennett GA, Ainsworth K, Trail B, Blackburn TP. BW 723C86, a 5-HT2B receptor agonist, causes hyperphagia and reduced grooming in rats. Neuropharmacology. 1997;36(2):233-239.
79. Nebigil CG, Etienne N, Schaerlinger B, Hickel P, Launay JM, Maroteaux L. Developmentally regulated serotonin 5-HT2B receptors. International Journal of Developmental Neuroscience: The Offcial Journal of the International Society for Developmental Neuroscience. 2001;19(4):365-372.
80. Loo H, Hale A, D'Haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. International Clinical Psychopharmacology. 2002;17(5): 239-247.